The Current Role of Corticosteroids in the Treatment of Retinal Vascular Disease
Given the vast number of Americans with or at risk for diabetes, and given that 40% to 45% of patients diagnosed with diabetes have diabetic retinopathy (DR) and thus are at risk for diabetic macular edema (DME), it is crucial that ophthalmologists are informed of the emerging treatment options for these patients in order to preserve or improve visual acuity and reduce the risk of low vision or blindness. Furthermore, there remains a great deal of confusion among ophthalmologists regarding the appropriate current use of corticosteroid therapy in patients with retinal vascular conditions.

After completing this activity, participants will have improved their ability to describe the pathophysiology of macular edema (ME), from DR, CRVO/BRVO; summarize the currently available data supporting the use of local corticosteroid therapy to treat ME associated with DR, CRVO/BRVO, as monotherapy or in combination regimens; and describe the practical considerations for local ophthalmic corticosteroid therapy and the currently available data supporting their use to treat ME. » Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.